louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06814977: An Acupuncture Study for Breast Cancer Survivors With Joint Pain on Hormonal Therapies
Official title: Researching the Implementation of Acupuncture for Aromatase Inhibitor-related Arthralgias in Diverse Underserved Breast Cancer Survivors (ReIMAGINE)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Breast Cancer
Breast Cancer Female
Breast Cancer Stage I
Breast Cancer Stage II
Breast Cancer Stage III
Breast Cancer Stage IIIB
Breast Cancer Stage IIIc
Breast Cancer, Male
Keywords: history of breast cancer
breast cancer stage I
breast cancer stage II
breast cancer stage III
breast cancer stage IIIb
breast cancer stage IIIc
acupuncture
breast cancer
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2025-02-07
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see whether acupuncture is a practical (feasible) treatment for breast cancer survivors with joint pain on hormonal therapies.


Eligibility criteria: Inclusion Criteria:

* English- or Spanish-speaking
* Black, Asian, and/or Hispanic women with a history of stage I, II, or III BC (transgender males are eligible to enroll)
* No evidence of current BC disease
* Receiving AI for at least 28 days with plan to continue for another 14 weeks
* Worst pain rated ≥4 on a 0-10 scale in the preceding week
* ≥15 days with pain in the past 30 days
* Pain lasting ≥1 month
* Pain attributed to AI as reported by the patient
* Willing and able to complete questionnaires and other study activities
* Willing and able to provide informed consent for the trial

Exclusion Criteria:

* All Stage IV Cancer
* Active oncological disease
* Completed chemotherapy, surgery, or radiation \<4 weeks prior to study
* Pain attributed to inflammatory arthritis (e.g., rheumatoid arthritis, gout)
* Procedures involving affected joints within the last month or planned in the next 14 weeks
* Acupuncture use for pain in the past year
* Implanted electronic device (e.g., pacemaker)

Primary outcomes:
measure: Study feasibility as measured by rates of enrollment
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center (All protocol activites)
state: New York
city: Richmond Hill
country: United States
facility: Jamaica Hospital Medical Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Kevin Liou, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00509977: Study of Light Treatment and Laser Treatment for Melasma
Official title: A Randomized, Rater-blinded, Split-face Comparison of the Efficacy of Intense Pulse Light vs. Q-switched Nd:Yag Laser for the Treatment of Melasma.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Melasma
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2007-08-01
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Detailed description: The objective of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of melasma lesion measuring at least 4 square centimeters.
* Age 18-75 years.
* Good health.
* Willingness and ability to understand and provide informed consent for participation in the study.
* Ability to communicate with the investigator.
* Must be willing to forgo other treatment options for melasma during the course of the study.

Exclusion Criteria:

* Inability to understand the protocol or to give informed consent.
* Mental illness.
* Under 18 years of age and over 75 years of age.
* Laser treatment in the last 6 months before enrollment.
* Isotretinoin within the past year.
* Lidocaine allergy.
* History of herpes simplex viral infection.
* Concurrent active disease to facial area (i.e acne).
* Bleeding disorder.
* History of abnormal wound healing.
* History of abnormal scarring.

Primary outcomes:
measure: Melasma Area and Severity Index
timeFrame: 20 weeks
Secondary outcomes:
measure: Safety
timeFrame: 20 weeks
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University Feinberg School of Medicine, Department of Dermatology
state: Illinois
Study officials:
affiliation: Northwestern University
name: Murad Alam, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Collyer J, Boone SL, White LE, Rademaker A, West DP, Anderson K, Kim NA, Smith S, Yoo S, Alam M. Comparison of treatment of cherry angiomata with pulsed-dye laser, potassium titanyl phosphate laser, and electrodesiccation: a randomized controlled trial. Arch Dermatol. 2010 Jan;146(1):33-7. doi: 10.1001/archdermatol.2009.318.
Clinical trial NCT01943877: Propolis In The Treatment Of Periodontitis
Official title: Propolis In The Treatment Of Chronic Periodontitis - A Clinicomicrobiologic Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Periodontitis
Lead sponsor: Rajarajeswari Dental College & Hospital
Sponsor class: OTHER
First posted: 2013-09-17
Enrollment: 20
Sex: ALL
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was conducted to evaluate by clinical and microbiological parameters the effect of locally delivered propolis as an adjunct to scaling and root planing in the treatment of chronic periodontitis.

Detailed description: Materials and Methods: 20 subjects diagnosed with chronic periodontitis were recruited to participate in split-mouth design and provided informed consent. Subgingival plaque sampling and clinical recording at baseline, 15 days and 1 month was performed. The patients received scaling and root planing, followed by Propolis administration subgingivally in the test sites. Significant differences between test and control were evaluated using the Mann-Whitney U test and Wilcoxon rank test.

Eligibility criteria: Inclusion Criteria:

* good general health
* chronic periodontitis
* minimum of 20 natural teeth with at least one pocket per quadrant
* probing depth (PD) between 5 and 8 mm.

Exclusion Criteria:

* subgingival instrumentation within 3 months
* antibiotic therapy within 3 months prior to the start of the study;
* smokers
* pregnant or nursing women
* intolerance or allergy to honey products

Primary outcomes:
measure: Change in the probing pocket depth and clinical attachment level
timeFrame: three time points of baseline,2 weeks, 4 weeks
Secondary outcomes:
measure: change in gingival index and microbiological changes
timeFrame: three time points baseline, 2 weeks, 4 weeks.
Other outcomes:
Locations:
city: Bangalore
country: India
facility: Rajarajeswari Dental College and Hospital
state: Karnataka
Study officials:
References:
Clinical trial NCT04038177: Superset Strength Training for Time-efficiency
Official title: Superset Strength Training for Time-efficiency - A Randomized Controlled Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sedentary Lifestyle
Keywords: Resistance training
Muscle strength
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
First posted: 2019-07-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Physical inactivity is a global challenge and there is an urgent need to find strategies to increases people's activity levels. Strength training is one of the activities that is recommended to engage in regularly by both the American College of Sports Medicine and the World Health Organization. Understanding how strength training can be done effectively without spending much time could potentially increase people's involvement in strength training, as lack of time often is reported as barrier to training. Superset strength training can potentially be a time-efficient way of strength training, as this training method has been found to take half the time of the traditional ways of training.

The aim of the present study is therefore to compare the effects of superset strength training and traditional strength training on muscular strength, body composition and fatigue.


Eligibility criteria: Inclusion Criteria:

* living in Trøndelag
* did not perform weekly strength training during the past 6 months.

Exclusion Criteria:

* any known severe somatic condition (e.g., autoimmune and systemic inflammatory diseases, cancer, severe osteoporosis)
* any known severe psychiatric condition
* other contraindications for heavy resistance training (e.g. shoulder pain).

Primary outcomes:
measure: Change in muscular strength
timeFrame: 3 months
Secondary outcomes:
measure: Change in body weight
timeFrame: 3 months
measure: Change in muscle mass
timeFrame: 3 months
measure: Change in body composition fat mass
timeFrame: 3 months
measure: Change in body composition BMI
timeFrame: 3 months
Other outcomes:
measure: Training load
timeFrame: continuously for 3 months
measure: Training volume
timeFrame: continuously for 3 months
measure: Perceived exhaustion
timeFrame: continuously for 3 months
measure: Participant's experiences with the intervention
timeFrame: 3 months
Locations:
city: Trondheim
country: Norway
facility: Norwegian University of Science and Technology
Study officials:
affiliation: Norwegian University of Science and Technology
name: Vegard moe Iversen, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Norwegian University of Science and Technology
name: Øystein Risa
role: STUDY_DIRECTOR
References:
Clinical trial NCT02205177: Youth Mayo Clinic Anxiety Coach Pilot Study
Official title: Expanding Access to Therapy for Childhood Anxiety Disorders Via Smart Phones - PILOT
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Keywords: Anxiety
Social Anxiety
Social Phobia
Separation Anxiety
Generalized Anxiety
GAD
Phobia
Panic
Agoraphobia
Obsessive Compulsive Disorder
OCD
Child
Adolescent
Smartphone
Teen
Youth
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2014-07-31
Enrollment: 10
Sex: ALL
Minimum age (years): 7
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This research study aims to test the feasibility and effectiveness of using the Mayo Clinic Anxiety Coach smartphone app as an addition to traditional therapy for the treatment of anxiety disorders in youth, particularly those youth who may have limited access to mental health treatment in the traditional clinical setting.

Detailed description: This research study aims to test the feasibility and effectiveness of using the Mayo Clinic Anxiety Coach smartphone app as an addition to traditional therapy for the treatment of anxiety disorders in youth, particularly those youth who may have limited access to mental health treatment in the traditional clinical setting. Therapist will provide CBT to patients with infrequent face-to-face contact and then will examine the acceptability, ease of use and need for contact.

Eligibility criteria: Inclusion Criteria:

1. Age 7 to 17
2. Primary diagnosis of:

   1. social phobia,
   2. separation anxiety disorder,
   3. panic disorder with and without agoraphobia,
   4. specific phobia, or
   5. obsessive compulsive disorder
3. A parent or other primary care giver available to participate with the child in all assessment and treatment activities
4. Estimated average intelligence
5. English speaking

Exclusion Criteria:

1. History of and/or current diagnosis of:

   1. psychosis,
   2. autism,
   3. bipolar disorder,
   4. mental retardation,
   5. oppositional defiant disorder,
   6. PTSD,
   7. selective mutism, or
   8. major depressive disorder
2. Current suicidality or recent suicidal behavior
3. Parent to be involved in study who is unable to adequately participate due to intellectual or psychiatric difficulties
4. Starting or changing the dosage of a psychiatric medication in the last two months

Primary outcomes:
measure: Mean Change From Baseline in Pediatric Anxiety Rating Scale (PARS) at Treatment Completion
timeFrame: Within 5 working days of Treatment Completion
Secondary outcomes:
measure: Number of Participants Who Completed the Subject Safety and Treatment Adherence Interview
timeFrame: Within 5 working days of Treatment Completion
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Stephen Whiteside, PhD, LP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06131177: Nutritional Interventions in Patients With Alcohol-associated Hepatitis
Official title: Comparing Nutritional Interventions in Patients With Alcohol-associated Hepatitis: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Alcoholic Hepatitis
Lead sponsor: Western University, Canada
Sponsor class: OTHER
First posted: 2023-11-14
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Alcohol-associated hepatitis (AH) is a life-threatening condition with high 90-days mortality (up to 40%) and limited treatment options. Previous studies have shown that decreased nutritional intake (less than 21 kcal/kg/day) is associated to a higher mortality compared to patients with a higher caloric intake. Additionally, it has been suggested that subjects with severe AH, should receive a high-protein diet, however, no specific trials have been carried out to address these questions. Thus, the investigators aim to compare nutritional interventions through a randomized controlled trial to assess if a strategy of peripheral parental nutrition (PPN) plus oral nutritional supplementation (ONS) improves outcomes in patients with severe AH. The investigators will compare standard oral intake, enhanced oral intake with IV fluid supplementation, and PPN plus ONS in patients admitted to hospital with severe AH. These results potentially will help guide practitioners on caloric benchmarks targets for patients with severe AH. This study will also assess specific risks and benefits of different nutritional interventions.


Eligibility criteria: Inclusion criteria:

* Adult (\>18 years) patients admitted with acute severe AH based clinical diagnosis according to NIAAA criteria
* Excessive alcohol consumption for more than 5 years in a row or interrupted
* No more than 60 days of abstinence before the onset of jaundice
* Bilirubin levels \>3 mg/dL (\>50 umol/L), AST\>50 IU/mL, AST/ALT ratio \> 1.5
* Abstinence of other causes of liver disease
* MELD score ≥ 20

Exclusion criteria:

* Age \< 18 years
* Pregnancy or lactation.
* Allergy or intolerance to the enhanced oral intake formulation or PPN formulation.
* Expected length of stay less than 48 hours.
* Contraindications to IV fluid or PPN administration (fluid overload, suspected bacteremia).
* Presence of drug-induced liver injury (DILI), ischemic hepatitis, biliary duct obstruction, viral hepatitis, autoimmune hepatitis, or Wilson's disease.
* Extrahepatic neoplasia with a life expectancy of less than 6 months.
* History of severe extrahepatic disease (e.g., chronic kidney failure requiring hemodialysis, severe heart disease (NYHA class ≥3), severe chronic lung disease (class ORO ≥3) that confers a survival of less than 6 months.

Primary outcomes:
measure: Transplant free survival (30 days)
timeFrame: 30 days
Secondary outcomes:
measure: Transplant free survival (90 days)
timeFrame: 90 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03197077: Optimisation of Follicular Recruitment in IVM Cycles
Official title: A Comparison Between Corifollitropin Alfa and Recombinant FSH for Follicular Recruitment in Women With Polycystic Ovaries Who Undergo IVM Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Infertility, Female
Polycystic Ovary Syndrome
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2017-06-23
Enrollment: 145
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 36
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will focus on important aspects related to follicle recruitment using exogenous gonadotropins in patients with polycystic ovaries:

1. Early follicle recruitment in patients with polycystic ovaries using corifollitropin alfa: does administration of this drug result in earlier and higher FSH (follicle stimulating hormone) concentrations above the threshold for follicle recruitment in an IVM (in vitro maturation) cycle preceded by oral contraceptive suppression, in comparison to normal daily administration of rFSH (recombinant follicle stimulating hormone, Puregon)?;
2. The maturation rate of the obtained oocyte-cumulus complexes in standard IVM media registered for clinical use: does stimulation with corifollitropin alfa versus recombinant FSH have an impact on the maturation rate and developmental capacity of the oocytes ?


Eligibility criteria: Inclusion Criteria:

1. Subfertile patients between 18-36 years old eligible for ART treatment
2. BMI 18-30
3. Polycystic ovaries (PCO) according to the Rotterdam criteria (at least 12 antral follicles per ovary as observed on a baseline ultrasound scan), with or without hyperandrogenism, with or without oligoamenorrhoea. In other words, patients are eligible if they have PCO morphology. A diagnosis of PCOS (polycystic ovary syndrome) based on Rotterdam criteria is not compulsory.

Exclusion Criteria:

1. Antral follicle count (AFC) \<24
2. Anti-müllerian hormone (AMH) \<3,25 in non-OCP (oral contraceptive pill) users and \<4,00 in current OCP users (using Elecsys platform (Roche Diagnostics))
3. Couples requesting PGD (preimplantation genetic diagnosis)
4. Non-obstructive azoospermia in the male partner

Primary outcomes:
measure: Number of COC
timeFrame: 5 days after the first gonadotropin injection (on the day of oocyte retrieval)
Secondary outcomes:
measure: Clinical pregnancy rate
timeFrame: At about 6 - 7 weeks gestation
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: UZ Brussel
Study officials:
References:
Clinical trial NCT04571177: PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke
Official title: Developing PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke Patients
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Acute Ischemic Stroke
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2020-09-30
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who are older than 18 years of age diagnosed with an acute supratentorial ischemic stroke within 48 hrs of onset will be enrolled into the study. Both male and female patients will be enrolled. We want diversity among participants in order to gain insightful information about acute supratentorial ischemic stroke as possible. A broad range in age, along with enrolling both male and female participants will allow greater diversity.

Brief summary: Adult patients who are diagnosed with an acute supratentorial ischemic stroke within 48 hrs of onset will be enrolled into the study. Participants will undergo both a CT Scan and PET scan within 7 days of onset. Participants will have the option to undergo a second PET scan with fluorodeoxyglucose (FDG).

Detailed description: Patients older than 18 years of age diagnosed with an acute supratentorial ischemic stroke within 48 hrs of symptom onset will be prospectively enrolled. Research imaging will be obtained before 7 days after symptom onset. The patient will receive the standardized treatment protocol at the hospital. Informed consent will be obtained from each patient or a substitute decision maker for each individual imaging study (CTP, Rb PET, and FDG PET). The patient will be given the option of undergoing the CTP imaging with the Rb PET only or both the Rb PET and FDG PET components.

Eligibility criteria: Inclusion Criteria:

* Age: \>18 yo
* Gender: male or female
* Acute (within 7 days from symptom onset) Supratentorial Ischemic Stroke

Exclusion Criteria:

* 1) Planned surgical intervention
* 2) Severely abnormal blood glucose level (will be excluded from FDG PET imaging)
* 3) Unable to undergo CTP or PET imaging (i.e. claustrophobia)
* 4) Pregnancy

Primary outcomes:
measure: Compare PET brain perfusion imaging to CTP
timeFrame: through study completion, 1 year from start of recruitment
Secondary outcomes:
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
Study officials:
affiliation: Associate Professor
name: Brian Buck
role: PRINCIPAL_INVESTIGATOR
References: